Calculation of pharmacokinetic and dosimetric characteristics of Lu-177--EDTMP – a potential drug for radionuclide therapy of bone metastases

«Radiation and Risk», 2023, vol. 32, No. 2, pp.96-109

DOI: 10.21870/0131-3878-2023-32-2-96-109


Matveev A.V. – Associate Prof., C. Sc., Phys.-Math. Dostoevsky OmSU. Contacts: 55A Mira av., Omsk, Russia, 644077. Tel.: +79043251774; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Petriev V.M. – Head of Lab., D. Sc., Biol., Prof. of MEPhI
Tishchenko V.K. – Lead. Researcher, D. Sc., Biol.
Minaeva N.G. – Sen. Researcher, C. Sc., Biol. A. Tsyb MRRC.
1 Dostoevsky Omsk State University, Omsk
2 A. Tsyb MRRC, Obninsk
3 National Research Nuclear University MEPhI, Moscow


Phosphonic acids labeled with beta-emitting radionuclides are promising radiopharmaceutical drugs for palliative therapy of bone metastases. Currently, the possibility of using a new osteotropic compound N,N,N’,N’-ethylenediaminetetrakis (methylene phosphonic acid) with lutetium-177 (177Lu-EDTMP) is being studied. The aim of the work is to develop a compartment mathematical model of the kinetics of 177Lu labeled osteotropic radiopharmaceutical drugs in the body of laboratory animals and calculate their pharmacokinetic and dosimetric characteristics based on it. To assess the stability of 177Lu-EDTMP in vivo, the characteristics of the distribution of free lutetium in the form of 177LuCl3 were also studied. To identify the model parameters and calculate the characteristics of radiopharmaceutical drugs, quantitative data on the bio-distribution of 177Lu-EDTMP and 177LuCl3 in the body of intact Wistar rats were used. A compartment model of kinetics has been developed and two approaches to the identification of its transport constants have been proposed – through the residual functional and using approximation by monoexponential functions. According to pharmacokinetic modeling, it was found that 177Lu-EDTMP is deposited in bone tissues (up to 55% of the administered dose). The calculated value of the apparent volume of distribution of 177Lu-EDTMP is approximately 200 times greater than the volume of blood plasma, the values of biological half-lives from bone tissues are 10-20 times higher than from internal organs. The excretion of 177Lu-EDTMP from the body occurs mainly through renal clearance. Comparative modeling with 177LuCl3 revealed high resistance of 177Lu-EDTMP in vivo. The highest values of absorbed doses are formed in the skeleton and kidneys with minimal radiation load on other internal organs and blood. The results obtained indicate the prospects for further studies of 177Lu-EDTMP and the possibility of its clinical application for the treatment of skeletal metastases.

Key words
pharmacokinetics, dosimetry, lutetium-177, radiopharmaceutical, EDTMP, modeling, nuclear medicine, radionuclide therapy, absorbed doses, bone metastases.


1. Murray I., Du Y. Systemic radiotherapy of bone metastases with radionuclides. Clin. Oncol., 2021, vol. 33, pp. 98-105.

2. Dash A., Pillai M.R., Knapp F.F. Jr. Production of 177Lu for targeted radionuclide therapy: available options. Nucl. Med. Mol. Imaging, 2015, vol. 49, no. 2, pp. 85-107.

3. Kuznetsov R.A., Bobrovskaya K.S., Svetukhin V.V., Fomin A.N., Zhukov A.V. Production of lutetium-177: process aspects. Radiokhimiya – Radiochemistry, 2019, vol. 61, pp. 381-395. (In Russian).

4. Zakaly M.H., Mostafa Y.A., Zhukovsky M. Labeling of ethylenediamine tetramethylene phosphonate with 153Sm and 177Lu, comparison study. Asia Pac. J. Oncol., 2020, vol. 1, pp. 38-44.

5. Tishchenko V.K., Petriev V.M., Matveev A.V., Fedorova A.V., Kuzenkova K.A. Biodistribution of 177Lu-EDTMP – a potential agent for radionuclide therapy of bone metastases. Khimiko-farmatsevticheskiy zhurnal – Pharmaceutical Chemistry Journal, 2022, vol. 56, no. 7, pp. 3-8. (In Russian).

6. Gleisner K.S., Chouin N., Gabina P.M., Cicone F., Gnesin S., Stokke C., Konijnenberg M., Cremonesi M., Verburg F.A., Bernhardt P., Eberlein U., Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur. J. Nucl. Med. Mol. Imaging, 2022, vol. 49, no. 6, pp. 1778-1809.

7. Sergienko V.I., Jelliff R., Bondareva I.B. Applied pharmacokinetics: fundamentals and clinical applications. Moscow, RAMS Publ., 2003. 208 p. (In Russian).

8. Galanin M.P., Khodzhaeva S.R. Development and testing for methods of solving stiff ordinary differential equations. Matematicheskoe modelirovanie i chislennye metody – Mathematical Modeling and Numerical Methods, 2014, no. 4, pp. 95-119. (In Russian).

9. Matveev A.V., Petriev V.M., Tishchenko V.K. Compartmental modeling of the kinetics of 188Re-labeled pen-taphosphonic acid in rats with bone callus. Khimiko-farmatsevticheskiy zhurnal – Pharmaceutical Chemistry Journal, 2021, vol. 55, no. 10, pp. 3-9. (In Russian).

10. Vatul’yan A.O. Mathematical models and inverse problems. Sorosovskiy obrazovatel’nyi zhurnal – Soros Educational Journal, 1998, no. 11, pp. 143-148. (In Russian).

11. Gosewisch A., Delker A., Tattenberg S, Ilhan H., Todica A., Brosch J., Vomacka L., Brunegraf A., Gildehaus F.J., Ziegler S., Bartenstein P., Böning G. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res., 2018, vol. 8, pp. 1-16.

12. Kumar C., Sharma R., Vats K., Mallia M.B., Das T., Sarma H.D., Dash A. Comparison of the efficacy of 177Lu-EDTMP, 177Lu-DOTMP and 188Re-HEDP towards bone osteosarcoma: an in vitro study. J. Radioanal. Nucl. Chem., 2019, vol. 319, no. 5, pp. 51-59.

Full-text article (in Russian)